Cytisus Scoparius Flower

Dosage for Cytisus Scoparius Flower extract is highly individualized and is never based on a standard 'one-size-fits-all' mg/kg formula. Instead, it is measured in Protein Nitrogen Units (PNU) or weight-to-volume (w/v) dilutions.

Diagnostic Testing Dosage

• Skin Prick Test (SPT): A single drop of a 1:10 or 1:20 w/v glycerinated extract is applied to the skin (usually the forearm or back), followed by a sterile prick through the drop.
• Intradermal Test: If the SPT is negative but clinical suspicion remains high, a 0.02 mL to 0.05 mL injection of a 1:1000 or 1:500 w/v aqueous dilution may be administered into the dermis.

Immunotherapy Dosage

• Build-up Phase: Treatment typically begins with a very low dose (e.g., 0.1 mL of a 1:100,000 w/v dilution). Doses are increased weekly or bi-weekly by 50% to 100% until the maintenance dose is reached.
• Maintenance Phase: The target dose is often 0.5 mL of a 1:100 or 1:10 w/v concentration, administered every 2 to 4 weeks.

Cytisus Scoparius Flower extract is generally considered safe for use in children, provided the child is old enough to cooperate with the testing and injection procedure (typically 5 years and older). Dosage follows the same titration principles as adult dosing, though clinicians may opt for a more conservative build-up schedule to monitor for systemic reactions. There is no specific evidence suggesting that pediatric patients require different concentrations, but the total volume of multiple allergens in a single injection must be carefully managed to avoid excessive local tissue trauma.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the systemic load of the extract is extremely low. However, patients with end-stage renal disease should be monitored for their ability to clear inflammatory mediators if a systemic reaction occurs.

Hepatic Impairment

No adjustments are typically necessary. However, since the alkaloid sparteine is metabolized by the liver, patients with severe hepatic failure should be observed closely during the initial high-dose maintenance phases.

Elderly Patients

Geriatric patients may have reduced skin reactivity (thinner dermis), which can lead to false-negative skin tests. Dosage for immunotherapy should be approached with caution in elderly patients with underlying cardiovascular disease, as they may be less tolerant of the epinephrine required to treat an accidental systemic reaction.

Cytisus Scoparius Flower extract is never for self-administration. It must be administered in a clinical setting equipped with 'crash carts' and emergency medications.

1. 1Preparation: The skin site (forearm or back) is cleaned with alcohol.
2. 2Administration: For testing, the skin is pricked or injected intradermally. For immunotherapy, the extract is injected subcutaneously into the outer aspect of the upper arm.
3. 3Observation: The patient must remain in the clinic for at least 30 minutes following any injection to monitor for signs of anaphylaxis.
4. 4Storage: Extracts should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze, as this can denature the allergenic proteins.

In immunotherapy, consistency is vital. If a dose is missed by more than one week, the next dose may need to be reduced to prevent a reaction. If several weeks are missed, the clinician may need to restart the build-up phase from a much lower concentration.

An 'overdose' in this context refers to the administration of a concentration higher than the patient's current tolerance level. Signs include rapid onset of hives, swelling of the throat, wheezing, and a drop in blood pressure. Emergency treatment with epinephrine (0.3 mg IM for adults) is required immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance.

Most patients undergoing testing or treatment with Cytisus Scoparius Flower will experience some form of localized reaction. These are generally considered part of the drug's expected pharmacological action.

• Local Wheal and Flare: A raised, red, itchy bump at the site of the skin test. This typically peaks at 15–20 minutes and resolves within 1–2 hours.
• Injection Site Swelling: In immunotherapy, a 'local' reaction (swelling up to the size of a half-dollar) is common. It may feel warm, itchy, or slightly painful and can last for 24 to 48 hours.
• Pruritus (Itching): Generalized itching near the administration site is frequently reported.

• Delayed Local Reactions: Swelling and redness that appear 6 to 12 hours after the injection. These are often treated with cold compresses and over-the-counter antihistamines.
• Fatigue: Some patients report feeling unusually tired for several hours following an immunotherapy injection.
• Headache: Mild tension-type headaches have been noted in clinical trials of allergenic extracts.

• Systemic Urticaria (Hives): Hives appearing on parts of the body away from the injection site.
• Rhinitis Symptoms: Sneezing, runny nose, or nasal congestion triggered by the systemic absorption of the allergen.
• Sparteine-Related Effects: In very high concentrations, the alkaloids in Cytisus Scoparius may cause mild dizziness or a temporary change in heart rate (bradycardia), though this is extremely rare with standardized extracts.

> Warning: Stop taking Cytisus Scoparius Flower and call your doctor immediately if you experience any of these symptoms of anaphylaxis.

• Upper Airway Obstruction: Feeling of a 'lump in the throat,' hoarseness, or difficulty swallowing.
• Lower Airway Obstruction: Wheezing, chest tightness, or a persistent cough.
• Cardiovascular Collapse: Dizziness, fainting, rapid or weak pulse, and a sharp drop in blood pressure (hypotension).
• Angioedema: Significant swelling of the lips, tongue, or around the eyes.
• Gastrointestinal Distress: Severe abdominal cramping, vomiting, or diarrhea occurring immediately after an injection.

Long-term use of Cytisus Scoparius Flower in immunotherapy is generally well-tolerated. There is no evidence that long-term exposure to these extracts increases the risk of autoimmune diseases or malignancy. The primary long-term 'effect' is the desired desensitization of the immune system. However, some patients may develop persistent nodules (small lumps) at the injection sites if the same area is used repeatedly without rotation.

While Cytisus Scoparius Flower may not have a specific individual black box warning for the plant itself, it falls under the General Black Box Warning for Allergenic Extracts. This warning states that allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. It mandates that these products only be administered by clinicians prepared to treat such reactions and that patients must be observed for a minimum of 30 minutes post-administration. Patients with unstable asthma or those taking beta-blockers are at a significantly higher risk of fatal outcomes if a reaction occurs.

Report any unusual symptoms to your healthcare provider.

Cytisus Scoparius Flower extract is a potent biological substance. It is intended only for use by physicians specializing in allergy and immunology. Patients must be informed that the very nature of the treatment—injecting a substance they are allergic to—carries an inherent risk of a systemic reaction. This risk is highest during the build-up phase of immunotherapy and during the transition to a new vial of extract.

No specific FDA black box warning exists for Cytisus Scoparius Flower as a standalone entity, but it is governed by the class-wide warning for Standardized Allergenic Extracts. This warning highlights the risk of anaphylactic shock and requires administration in a facility with emergency resuscitative equipment. It also notes that the risk of systemic reactions is increased in patients with symptomatic asthma or during periods of high natural allergen exposure (e.g., peak Scotch Broom pollination season).

• Anaphylaxis Risk: This is the primary concern. Patients must be screened for 'high-risk' status, including those with a history of severe previous reactions or those currently experiencing an asthma flare-up.
• Asthma Stability: Immunotherapy should never be administered if the patient's asthma is poorly controlled (e.g., FEV1 < 80% of predicted). Acute bronchospasm can be fatal during an allergic reaction.
• Cardiovascular Health: Patients with underlying heart disease may not tolerate the physiological stress of anaphylaxis or the administration of epinephrine.
• Alkaloid Sensitivity: Because Cytisus Scoparius contains sparteine, which has oxytocic (uterus-contracting) and anti-arrhythmic properties, patients with sensitive cardiac conduction or pregnancy should be monitored with extra care.

• Pre-Injection Assessment: Before every dose, the clinician must ask about the patient's current health, any recent asthma symptoms, and the reaction to the previous dose.
• Post-Injection Observation: A mandatory 30-minute wait time in the office is required.
• Peak Flow Monitoring: For asthmatic patients, a peak flow meter may be used before and after the injection to ensure airway stability.

Most patients can drive themselves to and from appointments. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive and must be monitored for several hours.

There is no direct interaction between alcohol and the extract. However, alcohol consumption can cause vasodilation, which may theoretically increase the rate of allergen absorption or mask the early symptoms of an allergic reaction. It is generally advised to avoid alcohol for several hours after an injection.

If a patient experiences a severe systemic reaction, the healthcare provider will re-evaluate the risk-benefit ratio of continuing the treatment. Discontinuation does not cause withdrawal symptoms, but the patient's allergy symptoms will likely return to their baseline level over time.

> Important: Discuss all your medical conditions with your healthcare provider before starting Cytisus Scoparius Flower.

• Beta-Blockers (e.g., Propranolol, Atenolol): These are strictly contraindicated in many allergy practices. If a patient on a beta-blocker has an anaphylactic reaction to Cytisus Scoparius Flower, the beta-blocker will prevent epinephrine from working effectively. This can lead to treatment-resistant, fatal anaphylaxis.
• MAO Inhibitors (e.g., Phenelzine): Cytisus Scoparius contains tyramine. When combined with MAOIs, this can lead to a hypertensive crisis (a dangerous spike in blood pressure).

• ACE Inhibitors (e.g., Lisinopril): These medications can increase the risk of severe systemic reactions and may interfere with the body's natural compensatory mechanisms during an allergic event.
• Tricyclic Antidepressants (TCAs): Like MAOIs, TCAs can potentiate the effects of epinephrine if it needs to be administered, leading to cardiac arrhythmias.

• Other Allergenic Extracts: If a patient is receiving multiple immunotherapy injections (e.g., for grass, dust mites, and Scotch Broom), the cumulative 'allergic load' increases the risk of a systemic reaction. Doses may need to be staggered.
• Antihistamines: While not dangerous, taking antihistamines before a skin test will suppress the 'wheal and flare' response, leading to a false-negative result. Antihistamines must be stopped 3 to 7 days before testing.

• High-Tyramine Foods: Since the flower contains tyramine, patients should be cautious with aged cheeses, cured meats, and red wine if they are receiving high-dose immunotherapy, though the risk is mostly theoretical.
• Legumes: Patients allergic to Scotch Broom may show cross-reactivity with other legumes (peanuts, soy, lentils). While eating these foods doesn't usually interact with the injection, it can complicate the diagnosis of symptoms.

• St. John's Wort: May affect the metabolism of the alkaloid components through CYP enzyme induction.
• Ephedra/Stimulants: Can increase the heart rate and blood pressure, potentially complicating the management of a systemic reaction.

• Skin Testing: As mentioned, antihistamines, H2 blockers (like famotidine), and certain antidepressants can interfere with skin test results.
• Total IgE Levels: Immunotherapy will eventually lead to changes in total and specific IgE levels, which is an expected pharmacological effect rather than an 'interaction.'

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Unstable Asthma: Patients with an FEV1 persistently below 70-80% of predicted or those who have had a recent acute exacerbation should not receive Cytisus Scoparius Flower injections. The risk of a fatal bronchospasm is too high.
• Recent Myocardial Infarction (Heart Attack): Patients with significant unstable cardiac disease cannot tolerate the stress of a systemic reaction or the emergency use of epinephrine.
• Previous Severe Reaction: If a patient has had a near-fatal reaction to this specific extract in the past, further use is typically contraindicated unless in a highly specialized desensitization protocol.
• Beta-Blocker Therapy: Due to the inability to treat anaphylaxis effectively.

• Pregnancy: While immunotherapy can be maintained during pregnancy, it is generally not started due to the risk of anaphylaxis-induced fetal hypoxia (lack of oxygen to the baby).
• Autoimmune Disorders: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis may have unpredictable immune responses to allergenic extracts.
• Severe Atopic Dermatitis: May make skin testing results impossible to interpret accurately.

Patients sensitive to Cytisus Scoparius Flower may also react to:

• Genista (Broom) species
• Lupinus (Lupine)
• Other Fabaceae members
• Certain Insect Venoms: Due to shared protein structures or the EPC classification context.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Cytisus Scoparius Flower.

Cytisus Scoparius Flower is classified generally in Pregnancy Category C. The primary risk is not the extract itself, but the potential for a systemic allergic reaction (anaphylaxis) in the mother. Anaphylaxis causes a sudden drop in blood pressure and uterine contraction, which can lead to fetal distress, miscarriage, or premature labor. Furthermore, the alkaloid sparteine is a known oxytocic agent that can stimulate uterine contractions. Most allergists recommend continuing maintenance doses during pregnancy if they are well-tolerated but advise against increasing the dose or starting new therapy.

It is unknown if the protein components or alkaloids from Cytisus Scoparius Flower pass into breast milk. However, because the amount injected is so small and the proteins are rapidly degraded, the risk to a nursing infant is considered negligible. The benefits of the mother having controlled allergy symptoms usually outweigh the theoretical risks.

Allergenic extracts are used in children as young as 5 years old. The primary concern in younger children is their inability to communicate early symptoms of a systemic reaction (e.g., an itchy throat or 'funny feeling'). Clinical studies have shown that immunotherapy in children can prevent the development of new sensitivities and reduce the risk of progressing from allergic rhinitis to asthma.

In patients over 65, the risk-benefit ratio must be carefully weighed. Older adults are more likely to have cardiovascular comorbidities that make them poor candidates for epinephrine. Additionally, the aging immune system (immunosenescence) may result in a less robust response to the immunotherapy, potentially reducing its efficacy.

There is no evidence that renal impairment alters the safety or efficacy of Cytisus Scoparius Flower extract. However, in the event of a systemic reaction, the kidneys' role in maintaining acid-base balance and fluid volume becomes critical. Patients with severe renal disease should be monitored closely for 45-60 minutes instead of the standard 30.

As the liver is responsible for metabolizing alkaloids like sparteine, patients with significant cirrhosis or hepatic failure should be observed for any signs of alkaloid toxicity, such as unusual bradycardia or gastrointestinal upset, though this is rare with standardized extracts.

> Important: Special populations require individualized medical assessment.

Cytisus Scoparius Flower extract acts as a specific antigen that interacts with the adaptive immune system. In sensitized individuals, the extract's proteins (allergens) cross-link IgE antibodies bound to the FceRI receptors on mast cells and basophils. This triggers a signal transduction pathway involving tyrosine kinases, leading to the release of pre-formed mediators (histamine) and the synthesis of new mediators (leukotrienes). In immunotherapy, the mechanism involves the induction of regulatory T cells (Tregs) that produce IL-10 and TGF-beta, which suppress the allergic response and promote the production of non-inflammatory IgG4 antibodies.

The pharmacodynamic effect of a skin test is almost immediate, with a peak response at 15–20 minutes. The immunomodulatory effects of immunotherapy are slow-onset, usually taking 3 to 6 months to become clinically apparent and 3 to 5 years to reach maximum permanent effect. The duration of effect after a completed course of immunotherapy can last for several years or even decades.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Subcutaneous/Intradermal) |

| Protein Binding | Minimal |

| Half-life | Hours (Mediators) / Years (Immunological Memory) |

| Tmax | 15-20 minutes (Skin Test) |

| Metabolism | Proteolysis / Hepatic (Sparteine) |

| Excretion | Renal (Metabolites) |

• Molecular Components: Includes proteins (allergens), flavonoids (quercetin), and quinolizidine alkaloids (sparteine, lupanine).
• Sparteine Formula: C15H26N2
• Solubility: Soluble in water and aqueous buffers; stabilized by glycerin.
• Structure: Complex mixture of high-molecular-weight proteins and low-molecular-weight alkaloids.

Cytisus Scoparius Flower belongs to the class of Allergenic Extracts. Within the FDA's EPC system, it is specifically categorized as a Standardized Insect Venom Allergenic Extract and Standardized Chemical Allergen, reflecting its role in standardized diagnostic panels and its potent biological activity.